The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
The partners are aiming to generate proteomic and phosphoproteomic data that they can include in Indivumed's global cancer database.
Researchers from A*Star and elsewhere have implicated a recessive mutation in CAMK2A in a neurodevelopmental disorder affecting a pair of siblings.
The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.
The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.
Each panel that the collaborators develop is expected to be highly multiplexed and syndromic, addressing clinically important infectious diseases in Asia.
GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.
New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.
Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.
In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.